| Human epidermal growth factor receptor 2 testing in breast cancer AC Wolff, MR Somerfield, M Dowsett, MEH Hammond, DF Hayes, ... Archives of pathology & laboratory medicine 147 (9), 993-1000, 2023 | 6513* | 2023 |
| College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer ME Hammond, DF Hayes, M Dowsett, DC Allred, KL Hagerty, S Badve, ... J Clin Oncol 28 (16), 2784-2795, 2010 | 6041* | 2010 |
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice … AC Wolff, MEH Hammond, DG Hicks, M Dowsett, LM McShane, ... Journal of clinical oncology 31 (31), 3997-4013, 2013 | 5616 | 2013 |
| Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update AC Wolff, MEH Hammond, KH Allison, BE Harvey, PB Mangu, ... Archives of pathology & laboratory medicine 142 (11), 1364-1382, 2018 | 2850 | 2018 |
| American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer GH Lyman, AE Giuliano, MR Somerfield, AB Benson III, DC Bodurka, ... Journal of clinical oncology 23 (30), 7703-7720, 2005 | 2421 | 2005 |
| 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline TJ Smith, J Khatcheressian, GH Lyman, H Ozer, JO Armitage, L Balducci, ... Journal of Clinical Oncology 24 (19), 3187-3205, 2006 | 1607 | 2006 |
| Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 S Adams, RJ Gray, S Demaria, L Goldstein, EA Perez, LN Shulman, ... Journal of clinical oncology 32 (27), 2959-2966, 2014 | 1411 | 2014 |
| Weekly paclitaxel in the adjuvant treatment of breast cancer JA Sparano, M Wang, S Martino, V Jones, EA Perez, T Saphner, AC Wolff, ... New England Journal of Medicine 358 (16), 1663-1671, 2008 | 1199 | 2008 |
| American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor–positive … EP Winer, C Hudis, HJ Burstein, AC Wolff, KI Pritchard, JN Ingle, ... Journal of clinical oncology 23 (3), 619-629, 2005 | 1148 | 2005 |
| Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis BB Barone, HC Yeh, CF Snyder, KS Peairs, KB Stein, RL Derr, AC Wolff, ... Jama 300 (23), 2754-2764, 2008 | 1076 | 2008 |
| Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update KH Allison, MEH Hammond, M Dowsett, SE McKernin, LA Carey, ... Journal of Clinical Oncology 38 (12), 1346-1366, 2020 | 1047 | 2020 |
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ... New England Journal of Medicine 372 (2), 134-141, 2015 | 853 | 2015 |
| Extending aromatase-inhibitor adjuvant therapy to 10 years PE Goss, JN Ingle, KI Pritchard, NJ Robert, H Muss, J Gralow, K Gelmon, ... New England Journal of Medicine 375 (3), 209-219, 2016 | 738 | 2016 |
| Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update JL Khatcheressian, P Hurley, E Bantug, LJ Esserman, E Grunfeld, ... Journal of Clinical Oncology 31 (7), 961-965, 2013 | 732 | 2013 |
| American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting JL Khatcheressian, AC Wolff, TJ Smith, E Grunfeld, HB Muss, VG Vogel, ... Journal of Clinical Oncology 24 (31), 5091-5097, 2006 | 666 | 2006 |
| Adjuvant chemotherapy in older women with early-stage breast cancer HB Muss, DA Berry, CT Cirrincione, M Theodoulou, AM Mauer, ... New England Journal of Medicine 360 (20), 2055-2065, 2009 | 657 | 2009 |
| Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane HJ Burstein, AD Elias, HS Rugo, MA Cobleigh, AC Wolff, PD Eisenberg, ... Journal of Clinical Oncology 26 (11), 1810-1816, 2008 | 647 | 2008 |
| TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer LA Carey, HS Rugo, PK Marcom, EL Mayer, FJ Esteva, CX Ma, MC Liu, ... Journal of clinical oncology 30 (21), 2615-2623, 2012 | 620 | 2012 |
| Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis KS Peairs, BB Barone, CF Snyder, HC Yeh, KB Stein, RL Derr, ... Journal of Clinical Oncology 29 (1), 40-46, 2011 | 517 | 2011 |
| Detection of cancer DNA in plasma of patients with early-stage breast cancer JA Beaver, D Jelovac, S Balukrishna, RL Cochran, S Croessmann, ... Clinical cancer research 20 (10), 2643-2650, 2014 | 446 | 2014 |
Daniel F. Hayesprofessor internal medicine在 umich.edu 的電子郵件地址已通過驗證
